Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
06 March 2024 - 9:00AM
Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology
company seeking to develop and commercialize universal-RAS/RAF
medicines for broad populations of cancer patients, announced today
that it will be presenting preclinical data on its lead program
IMM-1-104 at the American Association for Cancer Research (AACR)
annual meeting, held April 5-10 in San Diego, California.
Details for the poster presentation are as follows:
Title: Activity of IMM-1-104 alone or in combination
with chemotherapy in RAS-altered pancreatic cancer
modelsDate and Time: Tuesday Apr 9, 2024, 9:00 AM -
12:30 PM PTPoster Session: In Vivo Imaging and Humanized
ModelsLocation: Poster Section 9, Poster Board #19Abstract
Number: 4195
The abstract is available on the AACR Online
Program and will be published in the online Proceedings of the
AACR. Following presentation, the poster will be available on the
publications section of Immuneering’s website.
About Immuneering
Corporation
Immuneering is a clinical-stage oncology company
seeking to develop and commercialize universal-RAS/RAF medicines
for broad populations of cancer patients with an initial aim to
develop a universal-RAS therapy. The Company aims to achieve
universal activity through deep cyclic inhibition of the MAPK
pathway, impacting cancer cells while sparing healthy cells.
Immuneering’s lead product candidate, IMM-1-104, is an oral,
once-daily deep cyclic inhibitor currently in a Phase 1/2a study in
patients with advanced solid tumors harboring RAS mutations.
IMM-6-415 is an oral, twice-daily deep cyclic inhibitor and will be
evaluated in a Phase 1/2a study in patients with advanced solid
tumors harboring RAS or RAF mutations. The company’s development
pipeline also includes several early-stage programs. For more
information, please visit www.immuneering.com.
Media Contact:Gina NugentNugent
Communications617-460-3579gina@nugentcommunications.com
Investor Contacts:Laurence WattsGilmartin
Group619-916-7620laurence@gilmartinir.com or
Kiki Patel, PharmDGilmartin
Group332-895-3225kiki@gilmartinir.com
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Apr 2024 to May 2024
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From May 2023 to May 2024